CLSN: OVATION 2 Study 85% Enrolled… By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT Benzinga · Jun 18, 2022
Celsion: Q1 Earnings Insights Celsion (NASDAQ:CLSN) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Benzinga · May 16, 2022
Earnings Outlook For Celsion Celsion (NASDAQ:CLSN) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Celsion will report an earnings per share (EPS) of $-0.99. Benzinga · May 13, 2022
Celsion's Formulated DNA Plasmid COVID-19 Vaccine Candidate Shows Activity Against Two Strains Celsion Corporation (NASDAQ:CLSN) has presented its PLACCINE platform technology at the World Vaccine Congress. "PLACCINE is demonstrating the potential to be a powerful platform that provides for rapid design capability for targeting two or more different variants of a single virus in one vaccine," said Dr. Khursheed Anwer, Chief Science Officer at Celsion.… Benzinga · Apr 21, 2022
CLSN: DSMB Recommends Continuing to Dose Patients in OVATION 2 Study… By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT Benzinga · Apr 5, 2022
Celsion's Return On Capital Employed Insights According to Benzinga Pro data, during Q4, Celsion (NASDAQ:CLSN) posted sales of $125.00 thousand. Earnings were up 21.98%, but Celsion still reported an overall loss of $4.22 million. Benzinga · Apr 1, 2022
Celsion: Q4 Earnings Insights Celsion (NASDAQ:CLSN) reported its Q4 earnings results on Thursday, March 31, 2022 at 08:30 AM. Here's what investors need to know about the announcement. Benzinga · Mar 31, 2022
Celsion's Earnings Outlook Celsion (NASDAQ:CLSN) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that Celsion will report an earnings per share (EPS) of $-0.90. Benzinga · Mar 30, 2022